Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients

Inclusion Criteria: * Adult patient ≥ 18 years of age, * Chronic hemodialysis patient for at least 3 months, * Affiliated or beneficiary of a social security plan, * Having signed a written and informed consent. Exclusion Criteria: * Any indication for long-term oral anticoagulation (atrial fibrillation, venous thromboembolic disease, mechanical valve prostheses, intracardiac thrombosis, etc.) * Double anti-platelet aggregation for any reason or an aspirin dose greater than 160 mg/day * Uncontrolled hypertension (BP \> 180/110 mmHg) * Ischemic stroke within 30 days prior to inclusion * History of major unprovoked hemorrhage (leading to hospitalization or transfusion) regardless of age * Surgery within 30 days prior to inclusion * High-risk bleeding condition in addition to renal failure (such as known coagulation disorder, thrombocytopenia (\< 100G/L), active neoplasia of the digestive or urinary tract, or presence of intracranial vascular malformation) * Severe hepatic impairment * Use of strong CYP3A4 inducers, including rifampin, St. John's Wort, carbamazepine, phenytoin, phenobarbital * Non-compliant patients * Pregnant or breastfeeding women, women of childbearing age without effective contraception * Contraindication to the administration of an anticoagulant treatment such as anti-phospholipid antibody syndrome * Known allergy to rivaroxaban or to one of its excipients (lactose monohydrate) * Patients under guardianship or conservatorship * Patients already participating in an ongoing study or who have participated in a study that ended less than 30 days prior to the inclusion date.